Australia's largest stock trading and investment forum Australia's #1 stock forum

VOR

0.00%

39.5¢ vortiv limited

Share Price, page-64

First 64 Last

Share
Profile

Follow
BrianMcgee

187 Posts.

12

15/01/18

22:16

Post #: 30324632
Share

Originally posted by TonyIndo ↑

Hi all,

Happy New Year!

My hope is that TSN/DWX remain focussed on the areas that are already bringing in steady repeatable business revenue, rather than looking at other sectors (ex blockchain) for potential acquisitions, which in my view could be costly & very time consuming to get off the ground. A sustainable and profitable business is what the company needs to prove first and foremost and I must say I am very encouraged with the progress the company have made to date. Note, they only acquired DWX in August last year if memory serves me well.

The next realistic goal (at least in my eyes) I'd like to see them tick off is for DWX to hit the $4m mark in revenue per annum milestone, all while keeping costs down and margins on par or hopefully slightly higher. Is that an achievable target within a timeframe of 6-12 months since the acquisition? Well, if all has remained on track and they haven't had any clients drop off etc then this could be an attainable target. Remember, DWX were averaging approximately $3.3m revenue per annum over three years prior to the acquisition. I don't think a target of $4m in revenue per annum is too much of a stretch within that time frame I mentioned above. But for all this we'll have to wait and see.

Looking forward to what transpires over the next 6-12 months with the company.

All the best.

Tony

Expand

Wow. I hope Jeff has a little more ambition.

TSN Price at posting: 1.2¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

AI stocks: What to expect in 2024-25

CTT

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

LRL

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

NWC

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

ATH

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability